Google
BVS 株価分析 — Bioventus Inc (Healthcare >> Medical Devices)
BVS に関するよくある質問
BVSのPER（株価収益率）は？
Bioventus Inc（BVS）は現在PER 31.33倍で取引されています。
BVSのROE（自己資本利益率）は？
Bioventus IncのROEは15.08%です。
BVSの配当利回りは？
Bioventus Incの配当利回りは0.00%です。
BVSの品質スコア（Quality Score）は？
当社のAIはBVSの総合財務品質を100点中46点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
BVSは今が買い時ですか？
当社AIのタイミングスコアは100点中91点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
BVSはどのセクターに属しますか？
Bioventus IncはHealthcare >> Medical Devicesセクターに分類されます（NASDAQ市場）
BVS AI Analysis Summary
Our AI summary for BVS: Bioventus Inc (NASDAQ), Healthcare >> Medical Devices sector. The stock currently trades at a P/E of 31.33, ROE of 15.08%, a dividend yield of 0.00%. Its financial Quality Score stands at 46/100 — fundamentals below the market average. The AI Timing Score is 91/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 13.47
Price
0.30
(2.28%)
Day Change
|
|
|---|
BVS, ファンダメンタルスコアはnot good ( ファンダメンタル = 46) but テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEの伸びが低い
平均ROEが低い
ROAがROEに比べて低い
ROAの伸びが低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
44% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
2360
|
| Magic Formula Rank by ROE |
2360
|
| Magic Formula Rank by ROIC |
1954
|
| Price | 13.47 |
| PBV / Sector |
3.81 / -101.53
|
| Earning Per Share | 0.43 |
| PE / Sector |
31.33 / 31.42
|
| PEG or PE/Growth / Sector |
-0.38 / 0.35
|
| Average 1M Daily Value |
8.48 M
|
| Average 1W Daily Value |
11.07 M
GREAT
|
| Timing Factors |
|
71% |
| Financial Health |
|
43% |
| ポイントになる統計 |
|
56% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-04 08:01:16 |
| Symbol | BVS |
| Name | BIOVENTUS INC |
| Sector | Healthcare >> Medical Devices |
| Market | NASDAQ |
| Listed Shares | 67.75 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 892.24 / 20,008.89 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 4721 Emperor Boulevard, Durham, NC, United States, 27703
Phone: 919 474 6700
Website: https://www.bioventus.com
Employees: 940
Sector: Healthcare >> Medical Devices
Description: Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company's restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Medical Devices
Click a bubble to view stock details · Bubble size represents market capitalization share
